{"id":6288,"date":"2025-08-25T08:16:25","date_gmt":"2025-08-25T05:16:25","guid":{"rendered":"https:\/\/prostatefocaltherapies.com\/prostat-psma-pet-ct-ve-pet-mri\/"},"modified":"2025-09-26T06:13:45","modified_gmt":"2025-09-26T03:13:45","slug":"prostat-psma-pet-ct-ve-pet-mri","status":"publish","type":"page","link":"https:\/\/prostatefocaltherapies.com\/tr\/prostat-psma-pet-ct-ve-pet-mri\/","title":{"rendered":"Prostat PSMA PET-CT ve PET-MRI"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Prostat PSMA PET-CT ve PET-MRI<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

PSMA PET\/CT<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\"\"<\/p>

Prostatta ve ayr\u0131ca metastaz yapan prostat\u0131n \u00e7evre dokular\u0131nda tespit edilen kanserin cerrahi veya \u0131\u015f\u0131nla tedavisi bo\u015fa harcanan bir \u00e7aba olarak nitelendirilir. Tan\u0131y\u0131 hemen takiben metastaz varl\u0131\u011f\u0131n\u0131n\/yoklu\u011funun belirlenmesi, bu erkekler i\u00e7in daha optimal bir tedavi karar\u0131 i\u00e7in \u00e7ok \u00f6nemlidir. <\/p>

Prostat kanseri te\u015fhisi konan erkeklerin \u00e7o\u011fu, metastatik kanser i\u00e7in bir kan\u0131t belirlemek i\u00e7in ek testlere tabi tutulur. Bu, prostat kanseri genellikle kemiklere metastaz yapt\u0131\u011f\u0131 i\u00e7in y\u0131llard\u0131r geleneksel bir BT (bilgisayarl\u0131 tomografi) taramas\u0131 ve kemik taramas\u0131 ile ger\u00e7ekle\u015ftirilmektedir. <\/p>

Bununla birlikte, her iki g\u00f6r\u00fcnt\u00fcleme teknolojisinin de s\u0131n\u0131rlamalar\u0131 vard\u0131r. Her ikisi de tek tek prostat kanseri h\u00fccrelerini tan\u0131mlamak i\u00e7in o kadar iyi de\u011fildir, bu nedenle \u00e7ok k\u00fc\u00e7\u00fck t\u00fcm\u00f6rler g\u00f6z ard\u0131 edilebilir. Ve kemik taramalar\u0131, kanser d\u0131\u015f\u0131ndaki bir etiyolojinin (\u00f6rne\u011fin artrit) neden oldu\u011fu kemik hasar\u0131n\u0131 veya anormallikleri tespit edebilir ve gereksiz ek tahlillere yol a\u00e7abilecek “yanl\u0131\u015f pozitif” bulgulara neden olabilir. <\/p>

PSMA PET BT, metastaz riski y\u00fcksek \u015f\u00fcphesi ile prostat kanseri tan\u0131s\u0131 alan hastalarda kullan\u0131l\u0131r. Yani PSMA PET-BT erkeklerde metastatik t\u00fcm\u00f6rleri tan\u0131mlamak i\u00e7in de kullan\u0131lmaktad\u0131r. PSMA PET BT’nin bu t\u00fcm\u00f6rleri tespit edebilme yetene\u011fi; CT taramas\u0131 ve kemik taramas\u0131 gibi standart g\u00f6r\u00fcnt\u00fcleme y\u00f6ntemlerinden daha y\u00fcksekti. <\/p>

PSMA PET-BT’nin pelvik lenf d\u00fc\u011f\u00fcmleri ve kemikler dahil t\u00fcm uzak metastazlar i\u00e7in daha do\u011fru oldu\u011fu g\u00f6sterilmi\u015ftir. Radyasyona maruz kalma oran\u0131 da PSMA PET-BT’de daha d\u00fc\u015f\u00fckt\u00fc. <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

PSMA-PET Taramas\u0131 Nedir?\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Tarama, ilk tedaviden sonra tekrarlayan ve v\u00fccudun di\u011fer b\u00f6lgelerine yay\u0131lm\u0131\u015f kanserin yerini ve kapsam\u0131n\u0131 tespit edebilir. Prostat PET\/CT taramalar\u0131, kanseri tek BT taramalar\u0131ndan veya MRI taramalar\u0131ndan daha erken tespit edebilir. PSMA-PET taramalar\u0131 prostat t\u00fcm\u00f6rlerini te\u015fhis etmek i\u00e7in en hassas taramalard\u0131r. B\u00f6ylece di\u011fer tarama y\u00f6ntemleri taraf\u0131ndan g\u00f6z ard\u0131 edilen k\u00fc\u00e7\u00fck t\u00fcm\u00f6rleri tan\u0131mlayabilir. Bu taramalar, y\u00fcksek riskli veya metastatik prostat kanseri te\u015fhisi konan erkekler taraf\u0131ndan da kullan\u0131labilir. <\/p>

\"\"<\/p>

Bu taraman\u0131n uzun ad\u0131 galyum-68 PSMA PET-CT’dir. Taraman\u0131n iki b\u00f6l\u00fcm\u00fc vard\u0131r – bir x-\u0131\u015f\u0131n\u0131 bile\u015feni (CT) ve bir PET taramas\u0131. <\/p>

BT taramas\u0131: BT taramas\u0131, v\u00fccudun 3 boyutlu bir g\u00f6r\u00fcnt\u00fcs\u00fcn\u00fc olu\u015fturmak i\u00e7in farkl\u0131 y\u00f6nlerde x-\u0131\u015f\u0131nlar\u0131 kullan\u0131r.<\/p>

PSMA-PET taramas\u0131:<\/em> PET taramalar\u0131, belirli v\u00fccut b\u00f6lgelerini ayd\u0131nlatmak i\u00e7in radyoaktif bir leke kullan\u0131r. PSMA-PET taramalar\u0131, prostat kanseri h\u00fccrelerinin varl\u0131\u011f\u0131yla ili\u015fkili PSMA proteini i\u00e7eren v\u00fccut b\u00f6lgelerini ara\u015ft\u0131r\u0131r. Galyum-68, PET taramas\u0131n\u0131n radyoaktif k\u0131sm\u0131n\u0131 g\u00f6sterir. <\/p>

BT ve PET taramalar\u0131n\u0131n tek bir g\u00f6r\u00fcnt\u00fcde toplanan bulgular\u0131, prostat t\u00fcm\u00f6rlerinin v\u00fccuttaki yerini g\u00f6sterebilir.<\/p>

<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

PSMA PET CT Taramas\u0131 Nas\u0131l \u00c7al\u0131\u015f\u0131r?\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Pozitron emisyon tomografisi (PET) taramas\u0131, kan dola\u015f\u0131m\u0131na enjeksiyondan sonra v\u00fccutta az miktarda s\u0131v\u0131 radyoaktif madde al\u0131m\u0131n\u0131 izlemek i\u00e7in yap\u0131lan bir n\u00fckleer t\u0131p taramas\u0131d\u0131r. Bir\u00e7ok PET taramas\u0131, kanseri tespit etmek i\u00e7in bir t\u00fcr radyo etiketli \u015feker kullan\u0131r \u00e7\u00fcnk\u00fc bir\u00e7ok kanserin h\u0131zla b\u00fcy\u00fcmesi i\u00e7in \u015fekere ihtiyac\u0131 vard\u0131r. Kanserler PET taramas\u0131nda “parlak” olarak g\u00f6r\u00fcn\u00fcr ve standart BT taramas\u0131na k\u0131yasla ek bilgi sa\u011flar. <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t

PSMA-PET Taramas\u0131 ile Standart PET Taramas\u0131 Aras\u0131ndaki Fark Nedir?\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Di\u011fer kanserlerden farkl\u0131 olarak, prostat kanseri genellikle yava\u015f b\u00fcy\u00fcr ve genellikle standart PET taramalar\u0131nda g\u00f6r\u00fclmez. PSMA-PET taramas\u0131 i\u00e7in, bir\u00e7ok prostat kanseri h\u00fccresinde bulunan Prostat Spesifik Membran Antijeni veya PSMA ad\u0131 verilen bir proteini spesifik olarak hedef alan farkl\u0131 t\u00fcrde bir radyoaktif izleyici kullan\u0131yoruz. PSMA-PET taramas\u0131 milimetrik prostat kanserlerini g\u00f6rebilir, bu nedenle prostat kanserinin erken evrelerini ilk metastaz yapmaya ba\u015flad\u0131\u011f\u0131nda tespit etmek \u00e7ok iyidir. Bu, metastaz\u0131n varl\u0131\u011f\u0131n\u0131 ve yerini do\u011fru bir \u015fekilde de\u011ferlendirebilece\u011fimiz ve hastalar\u0131n bireysel durumlar\u0131 i\u00e7in daha iyi bir tedavi ayarlayabilece\u011fimiz anlam\u0131na gelir. <\/p><\/div>

<\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

PSMA PET BT i\u00e7in Kimler Uygundur?\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

G\u00fcn\u00fcm\u00fczde PSMA-PET taramalar\u0131;<\/p>

\"\"<\/p>

  • \u00e7o\u011funlukla lokalize prostat kanseri i\u00e7in cerrahi veya radyoterapi tedavisi sonras\u0131 PSA’s\u0131 artm\u0131\u015f erkekler taraf\u0131ndan kullan\u0131l\u0131r. Bu a\u015famada PSMA-PET taramalar\u0131, tedaviye ra\u011fmen metastaz yapan yeni t\u00fcm\u00f6rleri tespit etmek i\u00e7in en hassas taramalard\u0131r. <\/li>
  • lokalize y\u00fcksek riskli prostat kanseri te\u015fhisi konan ki\u015filer (BT veya kemik taramalar\u0131 ile g\u00f6sterilmeyen t\u00fcm\u00f6rler).<\/li>
  • Tan\u0131 an\u0131nda metastatik prostat kanseri olan hastalar<\/li>
  • Hastal\u0131k evresini belirlemek i\u00e7in<\/li>
  • biyopsi sonu\u00e7lar\u0131 negatif olsa bile t\u00fcm\u00f6r \u015f\u00fcphesi varsa,<\/li>
  • Di\u011fer tetkiklerdeki \u015f\u00fcpheli verileri netle\u015ftirmek.<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t

    PSMA PET CT Taramas\u0131n\u0131n Avantajlar\u0131 Nelerdir?\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t\t\t\t\t

    \"\"<\/p>

    • PSMA-PET taramalar\u0131, y\u00fcksek riskli prostat kanseri olan erkeklerde metastatik t\u00fcm\u00f6rleri tan\u0131 an\u0131nda tespit etmek veya d\u0131\u015flamak i\u00e7in BT ve kemik taramalar\u0131na k\u0131yasla daha do\u011frudur<\/li>
    • PSMA-PET taramalar\u0131n\u0131n daha optimal tedavi planlar\u0131n\u0131n planlanmas\u0131na olanak tan\u0131rlar.<\/li>
    • PSMA-PET taramas\u0131 yap\u0131lan erkekler, BT ve kemik taramalar\u0131na k\u0131yasla daha az radyasyona maruz kal\u0131yor.<\/li>
    • PSMA-PET taramas\u0131 yap\u0131lan erkeklerin belirsiz sonu\u00e7lar alma olas\u0131l\u0131\u011f\u0131 daha d\u00fc\u015f\u00fckt\u00fcr. (Belirsiz sonu\u00e7lar\u0131n g\u00f6r\u00fclme s\u0131kl\u0131\u011f\u0131 BT ve kemik taramalar\u0131nda %23, PSMA PET’te %7 idi). <\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
      \n\t\t\t\t\t\t
      \n\t\t\t\t\t
      \n\t\t\t
      \n\t\t\t\t\t\t
      \n\t\t\t\t\t\t
      \n\t\t\t\t\t
      \n\t\t\t
      \n\t\t\t\t\t\t
      \n\t\t\t\t
      \n\t\t\t\t\t

      PSMA PET\/MRI\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
      \n\t\t\t\t
      \n\t\t\t\t\t\t\t\t\t

      \"\"<\/p>

      PET\/MR g\u00f6r\u00fcnt\u00fcleme, manyetik rezonans ile yumu\u015fak doku morfolojik g\u00f6r\u00fcnt\u00fcleme ve pozitron emisyon tomografisi ile fonksiyonel g\u00f6r\u00fcnt\u00fclemeyi i\u00e7eren hibrit bir g\u00f6r\u00fcnt\u00fcleme teknolojisidir.<\/p>

      PET MR teknolojisi, iki farkl\u0131 t\u0131bbi tekni\u011fin bir araya getirilmesiyle olu\u015ftu\u011fu i\u00e7in geli\u015fmi\u015f v\u00fccut taramas\u0131 ve g\u00f6r\u00fcnt\u00fcleme imkan\u0131 sunar. Y\u00fcksek teknoloji \u00fcr\u00fcn\u00fc olan PET MR cihaz\u0131 ile 3 boyutlu de\u011ferlendirme yap\u0131labilmekte ve en hassas d\u00fczeyde bilgi elde edilebilmektedir. Bu tarama ve g\u00f6r\u00fcnt\u00fcleme teknolojisi, t\u00fcm kanser t\u00fcrlerinin te\u015fhisi i\u00e7in kullan\u0131l\u0131r. <\/p>

      PET ile \u00e7ekilen fonksiyonel g\u00f6r\u00fcnt\u00fclerin MRG’nin sa\u011flad\u0131\u011f\u0131 y\u00fcksek yumu\u015fak doku kontrast\u0131 ile birlikte de\u011ferlendirilmesi, \u00f6zellikle prostat bezi gibi anatomik korelasyonda BT g\u00f6r\u00fcnt\u00fclerinin yetersiz kald\u0131\u011f\u0131 dokularda devrim niteli\u011finde olmu\u015ftur. PET\/MRG’nin klinik kullan\u0131ma girmesi, prostat kanseri tan\u0131s\u0131 i\u00e7in yeni bir kap\u0131 a\u00e7m\u0131\u015ft\u0131r. Prostat spesifik membran antijeni (PSMA), pozitron emisyon tomografisi (PET) ile kapsaml\u0131 bir \u015fekilde incelenmi\u015ftir ve sonu\u00e7lar umut vericidir. Bu nedenle prostat kanseri g\u00f6r\u00fcnt\u00fclemesinde tan\u0131, primer evreleme, biyokimyasal n\u00fcks tespiti (BCR), terap\u00f6tik yan\u0131tlar\u0131n de\u011ferlendirilmesi ve tedavi planlamas\u0131 gibi farkl\u0131 klinik durumlarda PET\/MRG uygulamalar\u0131n\u0131n kullan\u0131m\u0131 artm\u0131\u015ft\u0131r. <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

      \n\t\t\t\t
      \n\t\t\t\t\t

      PSMA PET\/MR Hangi Durumlarda Tercih Edilir?\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
      \n\t\t\t\t
      \n\t\t\t\t\t\t\t\t\t

      \"\"<\/p>

      PSMA PET MR g\u00f6r\u00fcnt\u00fcleme tekni\u011finin ba\u015fl\u0131ca kullan\u0131m alanlar\u0131 \u015funlard\u0131r:<\/p>

      • <\/i> Prostat\u0131n i\u00e7 yap\u0131s\u0131n\u0131n daha iyi ay\u0131rt edilmesi gereken durumlarda (fokal tedavi i\u00e7in hastan\u0131n de\u011ferlendirilmesinde, PROSTAT KANSER\u0130 HAR\u0130TASI),<\/li>
      • <\/i> Prostat kanseri tan\u0131 ve y\u00f6netimi, evreleme, takip,<\/li>
      • <\/i> Prostat biyopsisi rehberli\u011fi ve prognoz belirleme amac\u0131yla,<\/li>
      • <\/i> Prostat bezinde santral zon gibi iyi huylu radyofarmas\u00f6tik tutulum ile patolojik tutulumun ayr\u0131m\u0131nda,<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
        \n\t\t\t\t\t\t
        \n\t\t\t\t\t
        \n\t\t\t
        \n\t\t\t\t\t\t
        \n\t\t\t\t\t\t
        \n\t\t\t\t\t
        \n\t\t\t
        \n\t\t\t\t\t\t
        \n\t\t\t\t
        \n\t\t\t\t\t

        PSMA PET\/MRI Taramas\u0131 Nas\u0131l Yap\u0131l\u0131r?<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
        \n\t\t\t\t
        \n\t\t\t\t\t\t\t\t\t

        PET MR taramas\u0131 yapt\u0131rmadan \u00f6nce, g\u00f6r\u00fcnt\u00fcleme ve taraman\u0131n daha ba\u015far\u0131l\u0131 olabilmesi i\u00e7in hastalar\u0131n uymas\u0131 gereken baz\u0131 kurallar vard\u0131r. Hastalar taramadan 24 saat \u00f6nce yorucu aktivitelerden ve egzersizlerden ka\u00e7\u0131nmal\u0131d\u0131r. Ancak taramadan 6 saat \u00f6nce herhangi bir yiyecek t\u00fcketmemelidir. Bunun nedeni, kan \u015fekerinin normal bir seviyede tutulmas\u0131 gerekti\u011fidir. Kan \u015fekeri de\u011ferlerinin y\u00fcksek ya da d\u00fc\u015f\u00fck olmas\u0131 tarama sonu\u00e7lar\u0131n\u0131 etkiler. <\/p>

        \"\"<\/p>

        V\u00fccudunuzda metal veya t\u0131bbi\/mekanik cihazlar varsa doktorunuzu bilgilendirmelisiniz. Kalp piliniz, defibrilat\u00f6r\u00fcn\u00fcz, serebral anevrizma klipsiniz veya metal i\u015fitme cihaz\u0131n\u0131z varsa bu muayene YAPILAMAZ. \u0130\u015flemden \u00f6nce t\u00fcm tak\u0131lar\u0131n\u0131z\u0131 ve i\u015fitme cihaz\u0131, metal fermuarl\u0131 kot pantolon, piercing ve \u00e7\u0131kar\u0131labilir di\u015f malzemesi gibi metal objelerinizi \u00e7\u0131karmal\u0131s\u0131n\u0131z. <\/p>

        PET MR i\u015flemi s\u0131ras\u0131nda hastaya radyoaktif bir madde enjekte edilir. Bir\u00e7ok hasta v\u00fccuda giren bu radyoaktif maddenin \u00e7ok zararl\u0131 oldu\u011funu d\u00fc\u015f\u00fcnmektedir. Ancak verilen bu maddenin miktar\u0131 azd\u0131r, v\u00fccuda herhangi bir zararl\u0131 etki yaratmayacak \u015fekilde k\u0131sa s\u00fcreli olarak verilir. Bu y\u00f6n\u00fcyle normal PET uygulamalar\u0131na g\u00f6re daha az zararl\u0131d\u0131r. PET MR taramas\u0131na ba\u015flamadan \u00f6nce hastaya damardan radyoaktif s\u0131v\u0131 enjekte edilir. Bu i\u015flem \u00e7ok k\u0131sa s\u00fcrer. Verilen s\u0131v\u0131, radyoaktif olarak etiketlenmi\u015f molek\u00fcller i\u00e7erir. Bu s\u0131v\u0131 enjeksiyonundan sonra hasta kur\u015fun yal\u0131t\u0131ml\u0131 bekleme salonunda yar\u0131m saat dinlendirilir. Bu beklemenin amac\u0131 damar yoluyla verilen radyoaktif s\u0131v\u0131n\u0131n t\u00fcm v\u00fccuda yay\u0131lmas\u0131d\u0131r. Bekledikten sonra g\u00f6r\u00fcnt\u00fclenecek ve taranacak hasta cihaza al\u0131n\u0131r. PET MR taramas\u0131 bu cihazda yakla\u015f\u0131k 20 dakika devam eder. Detayl\u0131 ve y\u00fcksek \u00e7\u00f6z\u00fcn\u00fcrl\u00fckte elde edilen g\u00f6r\u00fcnt\u00fcler, i\u015flemin tamamlanmas\u0131n\u0131n ard\u0131ndan ilgili uzmanlar taraf\u0131ndan incelenir. Muayene sonras\u0131nda kanserli h\u00fccrenin v\u00fccutta nereye yay\u0131ld\u0131\u011f\u0131, hangi noktadan itibaren t\u00fcm v\u00fccuda yay\u0131lmaya ba\u015flad\u0131\u011f\u0131 ve t\u00fcm\u00f6rlerin v\u00fccutta nerede olu\u015ftu\u011fu belirlenir. <\/p>

        T\u00fcm i\u015flemler ortalama 40-45 dakika s\u00fcrmektedir. \u0130\u015flemde kullan\u0131lan radyoaktif madde olduk\u00e7a zarars\u0131zd\u0131r ve radyasyona maruz kalmadan tarama yap\u0131lmas\u0131 sa\u011flan\u0131r. Ayr\u0131ca PET MR \u00e7ok kullan\u0131\u015fl\u0131 bir g\u00f6r\u00fcnt\u00fcleme y\u00f6ntemidir \u00e7\u00fcnk\u00fc tek bir tarama ile daha iyi bir tarama ve g\u00f6r\u00fcnt\u00fc sa\u011flan\u0131r. PET MR, radyasyon \u00e7ocuklarda daha ciddi etkilere neden olabilece\u011fi i\u00e7in \u00e7ocuklarda yayg\u0131n olarak kullan\u0131labilen bir g\u00f6r\u00fcnt\u00fcleme tekni\u011fidir. <\/p>

        \"\"<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

        \n\t\t\t\t\t\t
        \n\t\t\t\t\t
        \n\t\t\t
        \n\t\t\t\t\t\t
        \n\t\t\t\t\t\t
        \n\t\t\t\t\t
        \n\t\t\t
        \n\t\t\t\t\t\t
        \n\t\t\t\t
        \n\t\t\t\t\t

        Neden PSMA PET \/ MRI'\u0131 Se\u00e7melisiniz?<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
        \n\t\t\t\t
        \n\t\t\t\t\t\t\t\t\t

        PET MRG, onkolojik olarak te\u015fhis koymak, kanser vakalar\u0131n\u0131 evrelemek ve tedavi yan\u0131t\u0131n\u0131 de\u011ferlendirmek i\u00e7in t\u00fcm v\u00fccut Manyetik Rezonans G\u00f6r\u00fcnt\u00fcleme (MRI) ve Pozitron Emisyon Tomografisinin (PET) g\u00fc\u00e7lerini birle\u015ftirir. Ayn\u0131 zamanda, PET MR baz\u0131 \u00e7ocuklarda ve gen\u00e7 eri\u015fkinlerde g\u00fcvenle kullan\u0131labilir, bu da radyasyon riskini \u00f6nemli \u00f6l\u00e7\u00fcde azalt\u0131r. <\/p>

        EVC\u0130L HAYVAN-MR;<\/p>

        • <\/i> MR radyasyon i\u00e7ermedi\u011fi i\u00e7in hasta PET MR’da PET CT incelemesinin 1\/3’\u00fc kadar radyasyon al\u0131r.<\/li>
        • <\/i> G\u00fc\u00e7l\u00fc bir g\u00f6r\u00fcnt\u00fcleme sistemi, 3 Tesla MRI testi ve y\u00fcksek \u00e7\u00f6z\u00fcn\u00fcrl\u00fckl\u00fc bir PET taray\u0131c\u0131 sunar.<\/li>
        • <\/i> Tan\u0131sal g\u00fcvenilirli\u011fi art\u0131r\u0131r.<\/li><\/ul>

          Sonu\u00e7 olarak, PSMA PET g\u00f6r\u00fcnt\u00fcleme prostat kanserinin tan\u0131 ve tedavisinde \u00f6nemli bir kilometre ta\u015f\u0131 haline gelmi\u015ftir. Evrelemenin yan\u0131 s\u0131ra primer lezyon tespitinde, biyopsi rehberli\u011finde ve prognozda \u00f6nemli bir g\u00f6r\u00fcnt\u00fcleme y\u00f6ntemidir. \u00d6zellikle PET\/MRI hibrit cihazlar\u0131n\u0131n kullan\u0131ma sunulmas\u0131yla birlikte, e\u015f zamanl\u0131 PSMA PET\/MR g\u00f6r\u00fcnt\u00fcleme, gelecekte tan\u0131 ve tedavi algoritmalar\u0131n\u0131 de\u011fi\u015ftirme potansiyeline sahiptir. Ancak \u015fu anda klinik uygulamada bilimsel \u00e7al\u0131\u015fmalar i\u00e7in kullan\u0131lmaktad\u0131r. <\/p>

          Sayfam\u0131z bilgilendirme ama\u00e7l\u0131d\u0131r. Tan\u0131 ve Tedavi i\u00e7in doktorunuza ba\u015fvurunuz. <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

          Prostat PSMA PET-CT ve PET-MRI PSMA PET\/CT Prostatta ve ayr\u0131ca metastaz yapan prostat\u0131n \u00e7evre dokular\u0131nda tespit edilen kanserin cerrahi veya \u0131\u015f\u0131nla tedavisi bo\u015fa harcanan bir \u00e7aba olarak nitelendirilir. Tan\u0131y\u0131 hemen takiben metastaz varl\u0131\u011f\u0131n\u0131n\/yoklu\u011funun belirlenmesi, bu erkekler i\u00e7in daha optimal bir tedavi karar\u0131 i\u00e7in \u00e7ok \u00f6nemlidir. Prostat kanseri te\u015fhisi konan erkeklerin \u00e7o\u011fu, metastatik kanser i\u00e7in bir […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-6288","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/prostatefocaltherapies.com\/tr\/wp-json\/wp\/v2\/pages\/6288","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/prostatefocaltherapies.com\/tr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/prostatefocaltherapies.com\/tr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/prostatefocaltherapies.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/prostatefocaltherapies.com\/tr\/wp-json\/wp\/v2\/comments?post=6288"}],"version-history":[{"count":1,"href":"https:\/\/prostatefocaltherapies.com\/tr\/wp-json\/wp\/v2\/pages\/6288\/revisions"}],"predecessor-version":[{"id":6292,"href":"https:\/\/prostatefocaltherapies.com\/tr\/wp-json\/wp\/v2\/pages\/6288\/revisions\/6292"}],"wp:attachment":[{"href":"https:\/\/prostatefocaltherapies.com\/tr\/wp-json\/wp\/v2\/media?parent=6288"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}